GlassScriptPhysician profile
Edgar H Hernandez
NPI 1861473506
$30,659.01
in general payments reported to CMS, 2019-2025
60 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $546 · 2021: $3,881 · 2022: $2,104 · 2023: $2,952 · 2024: $20K · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,188 · Food and Beverage: $3,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,972.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,187.50 |
| Food and Beverage | $3,254.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,404.61 | 2021-2024 | Ligasure |
| Stryker Corporation | $1,068.11 | 2021-2024 | Molli |
| Astrazeneca Pharmaceuticals LP | $685.18 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Focal Therapeutics, INC. | $660.52 | 2019-2020 | |
| Hologic INC | $454.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $339.35 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $251.39 | 2020-2025 | |
| Janssen Biotech, INC. | $233.78 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $217.33 | 2019-2024 | |
| Eisai INC. | $206.96 | 2021-2024 | |
| Endomagnetics LTD | $195.75 | 2023 | Magtrace, Magseed |
| Incyte Corporation | $183.51 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $183.49 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Hologic Sales and Service, LLC | $169.66 | 2022 | |
| Bioptics, INC. | $149.21 | 2020 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $135.13 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $130.82 | 2023-2025 | Libtayo |
| Genmab U.S., INC. | $117.62 | 2024-2025 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $117.28 | 2019-2025 | |
| Puma Biotechnology, INC. | $117.17 | 2019-2024 | |
| Amgen INC. | $97.66 | 2020-2022 | |
| Genentech USA, INC. | $79.36 | 2019-2025 | Alecensa, Itovebi, Tecentriq Hybreza |
| Glaxosmithkline, LLC. | $77.43 | 2023 | Ojjaara, Shingrix, Zejula |
| Tersera Therapeutics LLC | $75.28 | 2022-2025 | Zoladex |
| Genzyme Corporation | $68.63 | 2019-2025 | |
| Covidien LP | $66.99 | 2019 | |
| Pfizer INC. | $64.92 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $61.70 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sun Pharmaceutical Industries INC. | $61.58 | 2020-2023 | Yonsa, Odomzo |
| Allergan, INC. | $60.01 | 2021 | |
| Sobi, INC | $59.50 | 2024-2025 | |
| Seagen INC. | $56.29 | 2021-2023 | Adcetris, Padcev |
| Emd Serono, INC. | $56.13 | 2021-2023 | Bavencio |
| Exelixis INC. | $53.89 | 2022 | |
| Aveo Pharmaceuticals, INC. | $49.58 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.12 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $48.03 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.54 | 2022-2024 | Alunbrig |
| Lilly USA, LLC | $45.85 | 2021-2024 | Verzenio, Jaypirca |
| Davol INC. | $38.30 | 2020-2022 | |
| Smith+Nephew, INC. | $37.58 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.14 | 2022-2023 | Zepzelca |
| Celgene Corporation | $32.16 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $26.48 | 2023 | Givlaari |
| Recordati_rare_diseases_inc. | $25.02 | 2025 | Enjaymo |
| Baxter Healthcare | $24.28 | 2022 | |
| Deciphera Pharmaceuticals INC. | $22.40 | 2023 | Qinlock |
| Dova Pharmaceuticals | $21.24 | 2021 | |
| Becton, Dickinson and Company | $20.93 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.85 | 2025 | Sancuso |
| Beone Medicines USA, INC. | $18.40 | 2025 | Brukinsa |
| Innovation Technologies INC | $17.82 | 2024 | Irrisept |
| Stemline Therapeutics INC. | $17.25 | 2023 | Orserdu |
| Immunocore Limited | $17.21 | 2025 | Kimmtrak |
| Blueprint Medicines Corporation | $17.11 | 2023 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $14.19 | 2023 | Ultomiris |
| Janssen Pharmaceuticals, INC | $14.13 | 2024 | Xarelto |
| Caris Mpi, INC. | $14.04 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $13.52 | 2023 | Cosela |
| Merit Medical Systems INC | $10.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.